TRAVASOL 3.5% W/ ELECTROLYTES

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 3.5% W/ ELECTROLYTES (TRAVASOL 3.5% W/ ELECTROLYTES).

How it works

TRAVASOL 3.5% W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids (3.5% crystalline amino acids) and electrolytes for protein synthesis and maintenance of electrolyte balance in patients unable to meet nutritional needs enterally. The amino acids serve as substrates for protein synthesis, while electrolytes support cellular function and acid-base balance.

What the body does with it

Metabolism	Amino acids undergo hepatic metabolism via transamination, deamination, and urea cycle; branched-chain amino acids are metabolized in skeletal muscle; electrolytes are excreted or reabsorbed via renal mechanisms.
Excretion	Renal: 100% of infused amino acids and electrolytes are excreted renally as urea and electrolytes, respectively.
Half-life	Amino acids: ~5–10 min for free amino acids (rapidly cleared from plasma); electrolytes: not applicable as they are distributed and eliminated via homeostasis; clinical context: infusion requires continuous monitoring due to rapid clearance.
Protein binding	Amino acids: minimal (<10%) binding to plasma proteins; electrolytes: negligible (e.g., sodium, potassium, calcium are free ions).
Volume of Distribution	Amino acids: 0.3–0.5 L/kg (distributes primarily to extracellular fluid); electrolytes: varies by ion (e.g., Na+ 0.6–0.7 L/kg, K+ 4–5 L/kg). Clinical meaning: reflects rapid equilibration with extracellular space.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate (within minutes) upon infusion initiation for amino acid utilization and electrolyte effects.
Duration of Action	Intravenous: 2–4 hours for amino acid elevation after infusion cessation; electrolytes: sustained until balanced by renal excretion.

Classification & Brands

Dosing & administration

Intravenous: 500 mL to 2 L per day as part of total parenteral nutrition; infusion rate adjusted to meet nutritional requirements and clinical status.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal failure (GFR <30 mL/min) without appropriate electrolyte monitoring; adjust potassium, phosphate, and magnesium based on serum levels; may require reduced volume in moderate to severe impairment.
Liver impairment	Use with caution in Child-Pugh class B or C; monitor ammonia, electrolytes, and glucose; avoid branched-chain amino acid formulations; reduce protein content if encephalopathy present.
Pediatric use	Dose based on body weight: 1-2 g/kg/day of amino acids; typical infusion rate 0.5-1 mL/kg/hour; adjust electrolytes per serum levels and age-specific requirements.
Geriatric use	Start at lower end of adult dose; monitor renal function and fluid status closely; adjust volume to avoid fluid overload; check electrolytes frequently.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 3.5% W/ ELECTROLYTES (TRAVASOL 3.5% W/ ELECTROLYTES).

Breastfeeding	There is no data on the excretion of TRAVASOL components into breast milk. Due to the intravenous administration and composition of amino acids, electrolytes, and dextrose, it is unlikely to pose a risk to the nursing infant. M/P ratio is not available. Use only if clearly needed.
Teratogenic Risk	TRAVASOL 3.5% W/ ELECTROLYTES is a parenteral nutrition solution. No teratogenic risk is established; however, use during pregnancy should be based on clinical necessity as malnutrition poses fetal risks. Inadequate nutrition in any trimester can impair fetal growth and development.

Warnings & precautions

■ FDA Black Box Warning

Not for use in patients with inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria) due to risk of severe metabolic acidosis, hyperammonemia, or neurological injury.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Inborn errors of amino acid metabolism (e.g., PKU, MSUD)","Severe metabolic alkalosis or acidosis","Severe hepatic or renal impairment without adequate metabolic monitoring","Hypercapnia or hypoxia with respiratory acidosis"]

Clinical Precautions

Precautions

["Risk of metabolic complications including hyperglycemia, hyperammonemia, and azotemia","Fluid overload in patients with renal or cardiac impairment","Electrolyte imbalances: hyperkalemia, hypernatremia, or hypophosphatemia","Intravenous infusion may cause thrombosis or infection","Monitor liver function, serum electrolytes, blood glucose, and acid-base status"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRAVASOL 3.5% W/ ELECTROLYTES

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 3.5% W/ ELECTROLYTES (TRAVASOL 3.5% W/ ELECTROLYTES).

How it works

What the body does with it

Metabolism	Amino acids undergo hepatic metabolism via transamination, deamination, and urea cycle; branched-chain amino acids are metabolized in skeletal muscle; electrolytes are excreted or reabsorbed via renal mechanisms.
Excretion	Renal: 100% of infused amino acids and electrolytes are excreted renally as urea and electrolytes, respectively.
Half-life	Amino acids: ~5–10 min for free amino acids (rapidly cleared from plasma); electrolytes: not applicable as they are distributed and eliminated via homeostasis; clinical context: infusion requires continuous monitoring due to rapid clearance.
Protein binding	Amino acids: minimal (<10%) binding to plasma proteins; electrolytes: negligible (e.g., sodium, potassium, calcium are free ions).
Volume of Distribution	Amino acids: 0.3–0.5 L/kg (distributes primarily to extracellular fluid); electrolytes: varies by ion (e.g., Na+ 0.6–0.7 L/kg, K+ 4–5 L/kg). Clinical meaning: reflects rapid equilibration with extracellular space.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate (within minutes) upon infusion initiation for amino acid utilization and electrolyte effects.
Duration of Action	Intravenous: 2–4 hours for amino acid elevation after infusion cessation; electrolytes: sustained until balanced by renal excretion.

Classification & Brands

Dosing & administration

Intravenous: 500 mL to 2 L per day as part of total parenteral nutrition; infusion rate adjusted to meet nutritional requirements and clinical status.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal failure (GFR <30 mL/min) without appropriate electrolyte monitoring; adjust potassium, phosphate, and magnesium based on serum levels; may require reduced volume in moderate to severe impairment.
Liver impairment	Use with caution in Child-Pugh class B or C; monitor ammonia, electrolytes, and glucose; avoid branched-chain amino acid formulations; reduce protein content if encephalopathy present.
Pediatric use	Dose based on body weight: 1-2 g/kg/day of amino acids; typical infusion rate 0.5-1 mL/kg/hour; adjust electrolytes per serum levels and age-specific requirements.
Geriatric use	Start at lower end of adult dose; monitor renal function and fluid status closely; adjust volume to avoid fluid overload; check electrolytes frequently.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 3.5% W/ ELECTROLYTES (TRAVASOL 3.5% W/ ELECTROLYTES).

Breastfeeding	There is no data on the excretion of TRAVASOL components into breast milk. Due to the intravenous administration and composition of amino acids, electrolytes, and dextrose, it is unlikely to pose a risk to the nursing infant. M/P ratio is not available. Use only if clearly needed.
Teratogenic Risk	TRAVASOL 3.5% W/ ELECTROLYTES is a parenteral nutrition solution. No teratogenic risk is established; however, use during pregnancy should be based on clinical necessity as malnutrition poses fetal risks. Inadequate nutrition in any trimester can impair fetal growth and development.